Citadel Advisors’s Immunic IMUX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $332K | Buy |
21,620
+10,171
| +89% | +$125K | ﹤0.01% | 10898 |
|
|
2026
Q1 | $127K | Sell |
11,449
-15,232
| -57% | -$136K | ﹤0.01% | 11827 |
|
|
2025
Q4 | $142K | Sell |
26,681
-26,827
| -50% | -$197K | ﹤0.01% | 11362 |
|
|
2025
Q3 | $472K | Buy |
+53,508
| New | +$472K | ﹤0.01% | 9273 |
|
|
2025
Q1 | – | Sell |
-30
| Closed | -$324 | – | 14994 |
|
|
2024
Q4 | $300 | Sell |
30
-23,976
| -100% | -$302K | ﹤0.01% | 14350 |
|
|
2024
Q3 | $396K | Buy |
+24,006
| New | +$342K | ﹤0.01% | 8739 |
|
|
2024
Q2 | – | Hold |
0
| – | – | – | 14126 |
|
|
2024
Q1 | – | Hold |
0
| – | – | – | 14464 |
|
|
2023
Q3 | – | Sell |
-188
| Closed | -$3.61K | – | 14661 |
|
|
2023
Q2 | $4.72K | Sell |
188
-610
| -76% | -$10.2K | ﹤0.01% | 13574 |
|
|
2023
Q1 | $11.9K | Sell |
798
-1,722
| -68% | -$32K | ﹤0.01% | 13450 |
|
|
2022
Q4 | $35.3K | Buy |
+2,520
| New | +$68.7K | ﹤0.01% | 12556 |
|
|
2022
Q3 | – | Sell |
-49,655
| Closed | -$2.08M | – | 13080 |
|
|
2022
Q2 | $1.72M | Buy |
49,655
+46,217
| +1,344% | +$2.96M | ﹤0.01% | 5849 |
|
|
2022
Q1 | $389K | Sell |
3,438
-1,023
| -23% | -$118K | ﹤0.01% | 9977 |
|
|
2021
Q4 | $427K | Buy |
+4,461
| New | +$402K | ﹤0.01% | 10060 |
|
|
2021
Q3 | – | Sell |
-1,391
| Closed | -$137K | – | 14208 |
|
|
2021
Q2 | $171K | Buy |
+1,391
| New | +$192K | ﹤0.01% | 12354 |
|
|
2021
Q1 | – | Sell |
-2,313
| Closed | -$392K | – | 13439 |
|
|
2020
Q4 | $353K | Sell |
2,313
-497
| -18% | -$89.3K | ﹤0.01% | 8780 |
|
|
2020
Q3 | $522K | Buy |
+2,810
| New | +$460K | ﹤0.01% | 7227 |
|
|
2019
Q2 | – | Sell |
-144
| Closed | -$11K | – | 9498 |
|
|
2019
Q1 | $11K | Sell |
144
-33
| -19% | -$2.9K | ﹤0.01% | 9145 |
|
|
2018
Q4 | $13K | Sell |
177
-565
| -76% | -$66.1K | ﹤0.01% | 8868 |
|
|
2018
Q3 | $82K | Buy |
742
+653
| +734% | +$1.7M | ﹤0.01% | 8648 |
|
|
2018
Q2 | $245K | Buy |
+89
| New | +$206K | ﹤0.01% | 7551 |
|
|
2018
Q1 | – | Sell |
-96
| Closed | -$229K | – | 8512 |
|
|
2017
Q4 | $229K | Buy |
+96
| New | +$212K | ﹤0.01% | 6899 |
|
|
2016
Q1 | – | Sell |
-53
| Closed | -$246K | – | 7320 |
|
|
2015
Q4 | $246K | Buy |
+53
| New | +$173K | ﹤0.01% | 5514 |
|
|
2015
Q3 | – | Sell |
-11
| Closed | -$55K | – | 9044 |
|
|
2015
Q2 | $92K | Buy |
+11
| New | +$105K | ﹤0.01% | 7154 |
|
Other funds holding IMUX
BI
APM
B
LCM
JHC
WP
SCM
Citadel Advisors's IMUX Position: Q2 2026 in Review
Citadel Advisors increased its Immunic (IMUX) stake by 89% in Q2 2026, buying an estimated $125K and bringing the position to 21,620 shares worth $332K. The position accounts for ﹤0.01% of the portfolio, ranked #10898.
Citadel Advisors first reported a position in IMUX in Q2 2015 and has held it in 22 quarters since. The position peaked at $1.72M in Q2 2022. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.
- Citadel Advisors held 21,620 shares of Immunic worth $332K as of Q2 2026.
- Citadel Advisors bought 10,171 Immunic shares in Q2 2026, an estimated $125K.
- Immunic made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #10898 holding.
- Citadel Advisors first reported a position in Immunic in Q2 2015 and has held it in 22 quarters since.
- Citadel Advisors's Immunic position peaked at $1.72M in Q2 2022.
- 55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.